[Form 4] BIOLIFE SOLUTIONS INC Insider Trading Activity

Rhea-AI Filing Summary

Mathew Aby J., EVP & Chief Scientific Officer of BioLife Solutions, Inc. (BLFS), reported a sale of company stock. The filing shows a sale of 630 shares of common stock on 09/11/2025 at a price of $26.83 per share executed under a Rule 10b5-1 trading plan established 03/08/2024 to satisfy tax withholding obligations arising from the vesting of restricted stock. After the reported sale, the reporting person beneficially owned 351,421 shares, held directly. The form is signed by the reporting person on 09/15/2025.

Positive

• Pre-arranged Rule 10b5-1 plan used, indicating the sale was scheduled and compliant with insider trading rules
• Reporting person retains substantial direct ownership of 351,421 shares after the transaction, showing continued insider alignment
• Clear disclosure and signed Form 4 filed, meeting Section 16 reporting requirements

Negative

• Insider disposed of shares (630 shares sold), which slightly reduces insider holdings

Insights

Financial Analyst

TL;DR: Small, pre-planned sale for tax withholding; reporting person retains substantial ownership.

The filing documents a planned disposition of 630 shares at $26.83 under a Rule 10b5-1 plan adopted 03/08/2024 to cover tax withholding for vested restricted stock. This indicates the sale was pre-authorized rather than opportunistic trading. The reporting person continues to hold 351,421 shares directly, which represents a meaningful equity stake for alignment with shareholder interests. No other transactions, derivative positions, or amendments are reported in this document.

Corporate Governance Expert

TL;DR: Governance signals are routine: compliance with disclosure and use of a 10b5-1 plan.

The Form 4 is complete and signed, disclosing an insider sale executed under a documented 10b5-1 plan adopted March 8, 2024. Using a 10b5-1 plan for tax-related sales is a common governance practice that helps mitigate appearance of selective insider trading. The filing shows continued direct ownership of 351,421 shares, maintaining ongoing insider alignment with shareholders. No governance red flags, amendments, or unexplained transactions appear in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Mathew Aby J.

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2025		S(1)		630	D	$26.83	351,421	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Remarks:

	/s/ Aby J. Mathew	09/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did BLFS insider Mathew Aby J. report on the Form 4?

The filing reports a sale of 630 shares of BioLife Solutions common stock on 09/11/2025 at $26.83 per share.

Why were the shares sold according to the Form 4 for BLFS?

The sale was executed under a Rule 10b5-1 trading plan adopted 03/08/2024 to satisfy tax withholding obligations from vested restricted stock.

How many BLFS shares does Mathew Aby J. own after the reported transaction?

After the reported sale the reporting person beneficially owned 351,421 shares, held directly.

When was the Form 4 signed and filed for the BLFS transaction?

The Form 4 bears the reporting person’s signature dated 09/15/2025.

Does the Form 4 show any derivative transactions for BLFS by this reporting person?

No. The filing includes only a non-derivative sale of common stock and lists no derivative securities.